HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sgouros, G. Search for Related Content PubMed PubMed Citation Articles by Sgouros, G.

Dosimetry of Internal Emitters

Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Response and toxicity prediction is essential to rational implementation of cancer therapy. The biologic effects of radionuclide therapy are mediated via a well-defined physical quantity, the absorbed dose, which is defined as the energy absorbed per unit mass of tissue. The concepts, basic definitions, and different approaches to the clinical implementation of absorbed dose estimation are reviewed in this article. Ongoing efforts to improve the accuracy of dosimetry calculations are discussed, as well as studies examining the relationship between absorbed dose and response. Particular attention is placed on the marrow and kidney as dose-limiting organs. Finally, the potential role of radiobiologic modeling in helping to account for differences in dose rate and spatial distribution are reviewed. A treatment planning approach to radionuclide therapy will eventually require incorporation of biologic and radiobiologic considerations. Until such methods are developed and validated, absorbed dose remains an important variable—but still one of several— likely to predict response in an individual patient.

Key Words: radionuclide therapy • radiobiologic modeling • absorbed dose • treatment planning

This article has been cited by other articles:

				P. Zanotti-Fregonara, C. Champion, R. Trebossen, R. Maroy, J.-Y. Devaux, and E. Hindie Estimation of the {beta}+ Dose to the Embryo Resulting from 18F-FDG Administration During Early Pregnancy J. Nucl. Med., April 1, 2008; 49(4): 679 - 682. [Abstract] [Full Text] [PDF]

				M. Cremonesi, M. Ferrari, C. M. Grana, A. Vanazzi, M. Stabin, M. Bartolomei, S. Papi, G. Prisco, G. Martinelli, G. Paganelli, et al. High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment J. Nucl. Med., November 1, 2007; 48(11): 1871 - 1879. [Abstract] [Full Text] [PDF]

				J. C. Pichardo, A. A. Trindade, J. M. Brindle, and W. E. Bolch Method for Estimating Skeletal Spongiosa Volume and Active Marrow Mass in the Adult Male and Adult Female J. Nucl. Med., November 1, 2007; 48(11): 1880 - 1888. [Abstract] [Full Text] [PDF]

				A. R. Prideaux, H. Song, R. F. Hobbs, B. He, E. C. Frey, P. W. Ladenson, R. L. Wahl, and G. Sgouros Three-Dimensional Radiobiologic Dosimetry: Application of Radiobiologic Modeling to Patient-Specific 3-Dimensional Imaging-Based Internal Dosimetry J. Nucl. Med., June 1, 2007; 48(6): 1008 - 1016. [Abstract] [Full Text] [PDF]

				G. Sgouros Toward Patient-Friendly Cell-Level Dosimetry J. Nucl. Med., April 1, 2007; 48(4): 496 - 497. [Full Text] [PDF]

				W. Cai, K. Chen, K. A. Mohamedali, Q. Cao, S. S. Gambhir, M. G. Rosenblum, and X. Chen PET of Vascular Endothelial Growth Factor Receptor Expression J. Nucl. Med., December 1, 2006; 47(12): 2048 - 2056. [Abstract] [Full Text] [PDF]

				J. M. Brindle, A. A. Trindade, A. P. Shah, D. W. Jokisch, P. W. Patton, J. C. Pichardo, and W. E. Bolch Linear Regression Model for Predicting Patient-Specific Total Skeletal Spongiosa Volume for Use in Molecular Radiotherapy Dosimetry J. Nucl. Med., November 1, 2006; 47(11): 1875 - 1883. [Abstract] [Full Text] [PDF]

				M. Cremonesi, M. Ferrari, L. Bodei, G. Tosi, and G. Paganelli Dosimetry in Peptide Radionuclide Receptor Therapy: A Review J. Nucl. Med., September 1, 2006; 47(9): 1467 - 1475. [Abstract] [Full Text] [PDF]

				G A Kaltsas, D Papadogias, P Makras, and A B Grossman Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues Endocr. Relat. Cancer, December 1, 2005; 12(4): 683 - 699. [Abstract] [Full Text] [PDF]

				Y. Wu, X. Zhang, Z. Xiong, Z. Cheng, D. R. Fisher, S. Liu, S. S. Gambhir, and X. Chen microPET Imaging of Glioma Integrin {alpha}v{beta}3 Expression Using 64Cu-Labeled Tetrameric RGD Peptide J. Nucl. Med., October 1, 2005; 46(10): 1707 - 1718. [Abstract] [Full Text] [PDF]